CymaBay Therapeutics, Inc.·4

Jan 27, 4:54 PM ET

Dorling Janet 4

4 · CymaBay Therapeutics, Inc. · Filed Jan 27, 2022

Insider Transaction Report

Form 4
Period: 2022-01-25
Dorling Janet
Chief Commercial Officer
Transactions
  • Award

    Stock Option (right to buy)

    2022-01-25+67,00067,000 total
    Exercise: $2.94Exp: 2032-01-24Common Stock (67,000 underlying)
Footnotes (1)
  • [F1]The option vests as to 1/12 of the underlying shares monthly from January 1, 2022.

Documents

1 file
  • 4
    form4.xmlPrimary

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES